Sepsis Metabolomics

Study Overview
=================
Brief Summary
-----------------
The occurrence of sepsis and its relevant multiple organ dysfunction remain a major problem in intensive care units with high morbidity and mortality. The differentiation between non-infectious and infectious etiologies, severity and organ function evaluation, and prognostic assessment are all challenging in routine clinical practice. Many biomarkers have been suggested for these purpose; however sensitivity and specificity even of high-ranking biomarkers still remain insufficient. Recently, metabolic profiling has attracted interest for biomarker discovery. In this study, LC-MS/MS will be perform to identify serum metabolic biomarkers for differentiation of SIRS/sepsis, severity and organ function evaluation, and prognostic assessment among 65 patients. The investigators enrolled 35 patients who were diagnosed with sepsis, 15 patients who were diagnosed with SIRS, and 15 normal patients. Moreover, the sepsis were further divided into sepsis, severe sepsis, and sepsis patients before death. Small metabolites that were present in patient serum samples were measured by LC-MS/MS techniques and analyzed using multivariate statistical methods, such as Principal Component Analysis (PCA), Partial Least Squares-Discriminant Analysis (PLS-DA), and Orthogonal Partial Least Squares Discriminant Analysis. Based on the multivariate statistical analysis above, the investigators could distinguish sepsis from normal and SIRS; distinguish the difference among sepsis, severe sepsis and death. We hypothesis that some metabolites as identified in this study are promising biomarker candidates in the field of sepsis diagnosis and treatment.

Official Title
-----------------
Systemic Metabolic Changes of Sepsis Patients Revealed by an LC-MS/MS Based Metabolomic Approach

Conditions
-----------------
Normal Control, SIRS, Sepsis, Severe Sepsis, Death

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: male and female aged 18 years old and over; clinically confirmed infection; fulfilled at least two criteria of systemic inflammatory response syndrome core temperature higher than 38 °C or lower than 36 °C respiratory rate above 20/min, or PCO2 below 32 mmHg pulse rate above 90/min, and white blood cell count greater than 12,000/μl or lower than < 4,000/μl or less than 10% of bands. Exclusion Criteria: younger than 18 years of age; acquired immunodeficiency syndrome; reduced polymorphonuclear granulocyte counts (< 500 μL-1); died within 24h after admission into the ICU, or refused to participate in the study, or declined treatment during the period of observation.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Normal control<br>Healthy volunteers | |
| SIRS<br>temperature >38 ℃ or <36℃; pulse rate>90 beats/min; ventilatory rate>20 breaths/min or hyperventilation with partial pressure of arterial carbon dioxide (PaCO2)<32mmHg; white blood cell count>12,000μL-1 or <4000μL-1 or >10% immature cells | |
| sepsis<br>sepsis is defined as SIRS plus confirmed infection. | |
| severe sepsis<br>sepsis associated with organ dysfunction, hypoperfusion, or hypotension. sepsis with arterial hypotension, despite adequate fluid resuscitation. | |
| death<br>sepsis patients within 48 hours before death. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| death |  | sepsis patients within 48 hours before death | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Metabolomics, serum, sepsis, biomarkers